{
    "eid": "2-s2.0-85146218412",
    "title": "PARP1PRED: A WEB SERVER FOR SCREENING THE BIOACTIVITY OF INHIBITORS AGAINST DNA REPAIR ENZYME PARP-1",
    "cover-date": "2023-01-02",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Animal Science and Zoology",
            "@code": "1103",
            "@abbrev": "AGRI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "cheminformatics",
        "DNA repair",
        "machine learning",
        "PARP-1",
        "QSAR",
        "webserver"
    ],
    "authors": [
        "Tassanee Lerksuthirat",
        "Sermsiri Chitphuk",
        "Wasana Stitchantrakul",
        "Donniphat Dejsuphong",
        "Aijaz Ahmad Malik",
        "Chanin Nantasenamat"
    ],
    "citedby-count": 0,
    "ref-count": 87,
    "ref-list": [
        "Design of potential anti-tumor PARP-1 inhibitors by QSAR and molecular modeling studies",
        "The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending im-munopharmacology content and introducing the IU-PHAR/MMV Guide to MALARIA PHARMACOL-OGY",
        "fda approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer",
        "Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase",
        "Targeted cancer therapy: the next generation of cancer treatment",
        "Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3",
        "Random forests",
        "Targeting DNA repair in cancer: beyond PARP inhibitors",
        "Letter to the Editor: Stability of Random Forest importance measures",
        "A review on machine learning approaches and trends in drug discovery",
        "Prediction of PARP inhibition with proteochemometric modelling and conformal prediction",
        "ChEMBL web services: streamlining access to drug discovery data and utilities",
        "Olaparib for metastatic castration-resistant prostate cancer",
        "Novel poly(ADP-ribose) polymerase-1 inhibitors",
        "Parp-2 is required to maintain hematopoiesis following sublethal \u03b3-irradia-tion in mice",
        "Evolution of poly(ADP-ribose) polymer-ase-1 (PARP-1) inhibitors. From concept to clinic",
        "Design and synthesis of poly(ADP-ri-bose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-Tetrahydro-benzo[c][1,6]-and [c][1,7]-naphthyridin-6-ones",
        "Design and synthesis of poly ADP-ri-bose polymerase-1 inhibitors. 2. Biological evaluation of Aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic inju-ries",
        "Inhibition of poly(ADP-ribose) pol-ymerase in tumors from BRCA mutation carriers",
        "Access to cancer medicines deemed essential by oncologists in 82 countries: an in-ternational, cross-sectional survey",
        "BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology",
        "Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer",
        "PARPs and ADP-ribosyl-ation: recent advances linking molecular functions to biological outcomes",
        "Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation",
        "DNA repair pathways as targets for cancer therapy",
        "Talazoparib: first global approval",
        "Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling",
        "Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piper-azin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1\u2013DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs",
        "Transcription factor NF-\u03baB as target for SARS-CoV-2 drug discovery efforts using inflammation-based QSAR screening model",
        "Computer aided design of ex-periments",
        "FDA approval summary: Olaparib monother-apy in patients with deleterious germline BRCA-mu-tated advanced ovarian cancer treated with three or more lines of chemotherapy",
        "PubChem substance and compound da-tabases",
        "Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase",
        "Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer",
        "In silico screening identifies a novel potential PARP1 inhibitor targeting synthetic lethality in cancer treatment",
        "An open-label, multicenter, single-arm, phase ii study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer",
        "Experimental and computational approaches to esti-mate solubility and permeability in drug discovery and development settings",
        "HCVpred: A web server for predict-ing the bioactivity of hepatitis C virus NS5B inhibitors",
        "PARP1 inhibitors: antitumor drug design",
        "DNA-repair defects and olaparib in metastatic prostate cancer",
        "A decade of clinical development of PARP inhibitors in perspective",
        "ChEMBL: towards direct deposition of bioassay data",
        "4-[3-(4-Cyclopropanecar-bonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A novel bioavailable inhibitor of poly(adp-ribose) polymerase-1",
        "Functional interac-tion between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse",
        "Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer",
        "Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors",
        "Maximizing computational tools for successful drug discovery",
        "A practical overview of quantitative structure-activity relationship",
        "QSAR modeling of aromatase inhibition by flavonoids using machine learning approaches",
        "Availability, affordability, access, and pricing of anti-cancer medicines in low-and middle-income coun-tries: a systematic review of literature",
        "Identification of substituted pyra-zolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors",
        "Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)",
        "Design and synthesis of N-substi-tuted indazole-3-carboxamides as poly(ADP-ri-bose)polymerase-1 (PARP-1) inhibitors(\u2020)",
        "Discovery and structure\u2013activity relationship of novel 2,3-dihydrobenzofuran-7-carbox-amide and 2,3-dihydrobenzofuran-3(2h)-one-7-car-boxamide derivatives as poly(ADP-ribose)polymer-ase-1 inhibitors",
        "Scikit-learn: machine learning in Python",
        "Identification and SAR of novel pyr-rolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)",
        "Understanding structural characteristics of PARP-1 inhibitors through combined 3D-QSAR and molecular docking studies and discovery of new inhibitors by multistage virtual screening",
        "Synthesis of isoquinolinone-based tetracycles as poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors",
        "The mechanism of the elongation and branching reaction of Poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis11Edited by R. Huber",
        "Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches",
        "Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-car-boxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors",
        "ERpred: a web server for the prediction of subtype-specific es-trogen receptor antagonists",
        "Niraparib: First global approval",
        "DNA double-strand break repair in a cellular context",
        "Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase in-hibitor",
        "DNA double-strand break repair inhibitors as cancer therapeutics",
        "Structural implications for selective targeting of PARPs",
        "Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)",
        "Discovery and SAR of novel, potent and selective hexahydrobenzonaphthy-ridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)",
        "Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer",
        "PARP power: A structural perspective on PARP1, PARP2, and PARP3 in DNA dam-age repair and nucleosome remodelling",
        "Physicochemical approaches to drug absorption",
        "Prediction of physico-chemical parameters by atomic contributions",
        "QSAR study of H1N1 neuraminidase inhibitors from influenza a virus",
        "Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer",
        "PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints",
        "Struc-ture-based design, synthesis, and evaluation of inhibi-tors with high selectivity for PARP-1 over PARP-2",
        "Discovery of novel quinazoline-2,4(1H,3H)-dione derivatives as potent PARP-2 selective inhibitors",
        "Discovery of quinazoline-2,4(1H,3H)-dione derivatives containing 3-substituted piperizines as potent PARP-1/2 inhibitors\u2500design, synthesis, in vivo antitumor ac-tivity, and X-ray crystal structure analysis",
        "Synthesis and evaluation of a radi-oiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60015887",
            "affilname": "Faculty of Medicine Ramathibodi Hospital, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015887",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Snowflake",
            "@id": "126427969",
            "affilname": "Snowflake Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126427969",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Mahidol University",
        "National Research Council of Thailand"
    ]
}